--- title: "Suzhou Ribo Life Science Co. (6938) stock and investor profile" url: "https://aibio.space/companies/suzhou-ribo-life-science/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Suzhou Ribo Life Science Co. Ltd. (HKEX: 6938), China. The directory classifies it as Pharmaceuticals: Generic." --- 6938 Suzhou Ribo Life Science Co. Ltd. HKEX · China # Suzhou Ribo Life Science Co. (6938) news Suzhou Ribo Life Science Co. Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 6938, recorded under China. The directory classifies it as Pharmaceuticals: Generic. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest Suzhou Ribo Life Science Co. news We have not published a story on Suzhou Ribo Life Science Co. yet. When there is news, it will appear here. ## Suzhou Ribo Life Science Co. at a glance - **Ticker**: 6938 - **Listing**: HKEX - **Country**: China ### Related companies - [Zhejiang Shouxiangu Pharmaceutical Holding Co.](https://aibio.space/companies/zhejiang-shouxiangu-pharmaceutical/) SSE: 603896 - [Tibet Duo Rui Pharmaceutical Co.](https://aibio.space/companies/tibet-duo-rui-pharmaceutical/) SZSE: 301075 - [Haisco Pharmaceutical Group Co.](https://aibio.space/companies/haisco-pharmaceutical/) SZSE: 002653 - [Vigonvita Life Sciences Co.](https://aibio.space/companies/vigonvita-life-sciences/) HKEX: 2630 - [Realcan Pharmaceutical Group Co.](https://aibio.space/companies/realcan-pharmaceutical/) SZSE: 002589 - [Chongqing Taiji Industry (Group) Co.](https://aibio.space/companies/chongqing-taiji-industry/) SSE: 600129 - [Chongqing Jiheng Pharmaceutical Co.](https://aibio.space/companies/chongqing-jiheng-pharmaceutical/) SZSE: 002742 - [Beijing Kawin Technology Share-Holding Co.](https://aibio.space/companies/beijing-kawin-technology-share/) SSE: 688687 ### Also on HKEX - [Ocumension Therapeutics](https://aibio.space/companies/ocumension-therapeutics/) 1477 - [Keymed Biosciences](https://aibio.space/companies/keymed-biosciences/) 2162 - [JW (Cayman) Therapeutics Co.](https://aibio.space/companies/jw-cayman-therapeutics/) 2126 - [B&K Corporation](https://aibio.space/companies/b-k/) 2396 - [Xuanzhu Biopharmaceutical Co.](https://aibio.space/companies/xuanzhu-biopharmaceutical/) 2575 - [Tianda Pharmaceuticals](https://aibio.space/companies/tianda-pharmaceuticals/) 455 ## Questions about Suzhou Ribo Life Science Co. What is the ticker symbol of Suzhou Ribo Life Science Co.? Suzhou Ribo Life Science Co. Ltd. trades under the ticker 6938 on HKEX. Where is Suzhou Ribo Life Science Co. listed? Suzhou Ribo Life Science Co. Ltd. is listed on HKEX. Which country or territory is Suzhou Ribo Life Science Co. listed under? Our directory records Suzhou Ribo Life Science Co. Ltd. under China. What does Suzhou Ribo Life Science Co. do? Our directory classifies Suzhou Ribo Life Science Co. Ltd. as: Pharmaceuticals: Generic. This is a directory classification, not a description of the pipeline. What is the ISIN of Suzhou Ribo Life Science Co.? The ISIN recorded for Suzhou Ribo Life Science Co. Ltd. is CNE100007DS6. Does aibio.space cover Suzhou Ribo Life Science Co.? aibio.space lists Suzhou Ribo Life Science Co. Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Which companies are similar to Suzhou Ribo Life Science Co.? Companies in our directory listed in the same country and business area as Suzhou Ribo Life Science Co.: Zhejiang Shouxiangu Pharmaceutical Holding Co., Tibet Duo Rui Pharmaceutical Co., Haisco Pharmaceutical Group Co., Vigonvita Life Sciences Co., Realcan Pharmaceutical Group Co., Chongqing Taiji Industry (Group) Co.. ## Investor discussion: Suzhou Ribo Life Science Co. Members talk about Suzhou Ribo Life Science Co. (6938). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Suzhou Ribo Life Science Co., newest first. Each line links the filing it comes from. 1. 2026-10-19 Mergers Transaction under the Listing Rules: DISCLOSEABLE AND CONNECTED TRANSACTION ACQUISITION OF THE REMAINING 49.71% SHAREHOLDING IN A SUBSIDIARY INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; AND PROPOSED CHANGE OF REGISTERED CAPITAL AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1019/2026101900151.pdf) 2. 2026-06-30 Mergers Transaction under the Listing Rules: DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO ACQUISITION OF 25.93% EQUITY INTEREST IN AZEMIDITE. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063003181.pdf) 3. 2026-05-12 Financings Share or debt issue: CIRCULAR OF THE 2025 ANNUAL GENERAL MEETING. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0512/2026051200795.pdf) 4. 2025-12-30 Financings Share or debt issue: GLOBAL OFFERING. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1231/2025123100037.pdf) ## Press releases Headlines of Suzhou Ribo Life Science Co.'s own announcements, newest first. Each opens the full release on the newswire that carried it. 1. 2026-10-19 HKEXnews [DISCLOSEABLE AND CONNECTED TRANSACTION ACQUISITION OF THE REMAINING 49.71% SHAREHOLDING IN A SUBSIDIARY INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; AND PROPOSED CHANGE OF REGISTERED CAPITAL AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1019/2026101900151.pdf) 2. 2026-10-07 HKEXnews [VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL APPLICATION SUBMISSION OF RBD3133 INJECTION FOR OVERWEIGHT AND OBESITY](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1008/2026100800069.pdf) 3. 2026-09-07 HKEXnews [VOLUNTARY ANNOUNCEMENT - INCLUSION AS A CONSTITUENT OF HANG SENG COMPOSITE INDEX AND INCLUSION IN THE STOCK LIST OF STOCK CONNECT SOUTHBOUND TRADING LINK](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0907/2026090700217.pdf) 4. 2026-08-27 HKEXnews [INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0827/2026082701285.pdf) 5. 2026-07-29 HKEXnews [POSITIVE FINANCIAL INFORMATION ALERT](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0729/2026072901100.pdf) 6. 2026-07-28 HKEXnews [VOLUNTARY ANNOUNCEMENT - APPROVAL OF PHASE 2B CLINICAL TRIAL BY EMA OF CORE PRODUCT VORTOSIRAN FOR SPAF](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0728/2026072801213.pdf) 7. 2026-07-22 HKEXnews [VOLUNTARY ANNOUNCEMENT - POSITIVE PHASE 2A STUDY RESULTS OF CORE PRODUCT VORTOSIRAN FOR CAD](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0722/2026072200330.pdf) 8. 2026-07-13 HKEXnews [VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE UNDER THE SHARE REPURCHASE MANDATE](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0713/2026071301033.pdf) 9. 2026-07-10 HKEXnews [VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF H SHARES OF THE COMPANY BY A DIRECTOR](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0710/2026071000869.pdf) 10. 2026-07-03 HKEXnews [VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF H SHARES OF THE COMPANY BY A DIRECTOR](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0703/2026070301907.pdf) 11. 2026-07-02 HKEXnews [VOLUNTARY ANNOUNCEMENT - FIRST MILESTONE ACHIEVEMENT OF COLLABORATION WITH MADRIGAL](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0702/2026070200087.pdf) 12. 2026-06-30 HKEXnews [DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO ACQUISITION OF 25.93% EQUITY INTEREST IN AZEMIDITE](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063003181.pdf) 13. 2026-06-08 HKEXnews [VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE H SHARE INCENTIVE SCHEME AND ON-MARKET SHARE REPURCHASE](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0608/2026060800370.pdf) 14. 2026-06-05 HKEXnews [Articles of Association](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0605/2026060502028.pdf) 15. 2026-06-05 HKEXnews [POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0605/2026060502000.pdf) 16. 2026-05-27 HKEXnews [VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL APPLICATION SUBMISSION OF RBD1119 INJECTION FOR TREATMENT OF CORONARY ARTERY DISEASE](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0528/2026052800037.pdf) 17. 2026-05-12 HKEXnews [H Share Option Scheme](https://www1.hkexnews.hk/listedco/listconews/sehk/dod/en.html) 18. 2026-05-12 HKEXnews [H Share Incentive Scheme](https://www1.hkexnews.hk/listedco/listconews/sehk/dod/en.html) 19. 2026-05-12 HKEXnews [NOTICE OF ANNUAL GENERAL MEETING](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0512/2026051200803.pdf) 20. 2026-05-12 HKEXnews [CIRCULAR OF THE 2025 ANNUAL GENERAL MEETING](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0512/2026051200795.pdf) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open HKEX:6938 on TradingView](https://www.tradingview.com/symbols/HKEX-6938/). ## Listing details Suzhou Ribo Life Science Co. Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 6938, recorded under China. The directory classifies it as Pharmaceuticals: Generic. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Suzhou Ribo Life Science Co. Ltd. - **Ticker**: 6938 - **Listing**: HKEX - **Country or territory**: China - **Business scope**: Pharmaceuticals: Generic - **ISIN**: CNE100007DS6 - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/HKEX-6938/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/suzhou-ribo-life-science/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Suzhou Ribo Life Science Co. (6938) stock and investor profile", 2026-10-31, https://aibio.space/companies/suzhou-ribo-life-science/